Small Intestinal Bacterial Overgrowth: Microbiome Dysregulation, Gut-Brain Axis Disruption, and Systemic Consequences.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search protocol or primary human data
PubMed 42378001 · doi:10.1002/mnfr.70541
What was done
The authors synthesized literature on small intestinal bacterial overgrowth (SIBO), reviewing its multifactorial pathophysiology (including gut-brain axis dysregulation, dysbiosis, and motility impairment), systemic clinical associations, and therapeutic strategies including nonsystemic antibiotics, dietary interventions, and nutraceuticals.
What was found
The abstract reports no numerical findings or quantitative effect sizes. It qualitatively describes SIBO's systemic reach across metabolic, cardiovascular, neurological, dermatological, and autoimmune conditions, highlighting limitations of standard antibiotics (recurrence, resistance, microbiome disruption) and emphasizing that nutraceutical and dietary interventions need stronger clinical trial validation.
Why it matters
It frames SIBO as a systemic disorder linked to gut-brain axis and immune dysregulation rather than a purely localized gastrointestinal issue, proposing priorities for personalized diagnostic and treatment strategies.
Limits
The paper is a narrative review presenting no new empirical data, sample size, or systematic methodology. Specific efficacy rates, comparator outcomes, and quantitative metrics are not provided in the abstract.
Cited by
- supports Bile released upon eating has antimicrobial properties that clear out bacteria in the small intestine, protecting against SIBO.
- supports Bile salts possess antimicrobial properties that prevent microbes from overgrowing in the small intestine, and low stomach acid impairs bile function.